Members in attendance
Stacey Ness, Pharm.D., Kelly Ruby, Pharm.D., Al Heaton, RPh., Kathryn Lombardo, M.D., James Phillips, M.D., Dan Tomaszewski Pharm.D. Margaret Artz, RPh, Ph.D., Stuart Williams, J.D.

DHS staff present
Adam Pavek,PharmD., Sara Drake, RPh., MPH, MBA

Others in attendance
Katie Counts, Pharm.D.

Report of the Chair
In respect of time the chair bypassed the report of the chair.

Approval of the minutes
Minutes from the June 2014 meeting were reviewed and approved.

Old Business
None

New Business

Existing Drugs for PA Consideration

Carisoprodol: The committee discussed the Universal Pharmacy Policy Workgroups recommendation to require prior authorization on carisoprodol containing products. The committee reviewed the provider update and the proposed PA criteria and voted unanimously to require PA on carisoprodol.

Synagis PA Criteria 2014-2015: The committee discussed the 2014-2015 Synagis prior authorization criteria. The Synagis season will be a transition year for MHCP and MHCP providers. MHCP will continue to approve Synagis requests meeting the 2013-2014 criteria to allow time for providers to fully implement the new guidelines over the next year. The committee agreed with the criteria and recommended continuation of the PA following the same criteria as 2013-2014 season and re-reviewing the criteria for the 2015-2016 season.

New Drugs for Continued PA
The committee discussed Duavee (conjugated estrogens/bazedoxifene)
The committee recommended to the department that Duavee remain on PA by a unanimous vote. The committee recommended that clinical criteria require trial and failure of a bisphosphonate and an estrogen containing product.

The committee discussed Luzu (luliconazole cream 1%) The committee recommended to the department that Luzu remain on PA by a unanimous vote.

The committee discussed Lazanda (fentanyl citrate)
The committee recommended to the department that Lazanda remain on PA by a unanimous vote. The committee recommended that clinical criteria require failure of a preferred agent and on-label use.

The committee discussed Iprivask (desirudin)
The committee recommended to the department that Iprivask remain on PA by a unanimous vote. The committee recommended that clinical criteria prefer enoxaparin sodium.

The committee discussed Ragwitek and Grastek
The committee recommended to the department that Ragwitek and Grastek remain on PA by a unanimous vote. The committee recommended that clinical criteria require confirmation of allergen reactivity and prior use of subcutaneous immunotherapy.

The committee discussed Zykadia (ceritinib)
The committee recommended to the department that Zykadia remain on PA by a unanimous vote. The committee recommended that the drug be kept to on-label use.

The committee discussed Zontivity (vorapaxar)
The committee recommended to the department that Zontivity (vorapaxar) remain on PA by a unanimous vote. The committee recommended that clinical criteria include on-label use with aspirin and clopidogrel.

The committee discussed Sitavig (acyclovir)
The committee recommended to the department that Sitavig (acyclovir) remain on PA by a unanimous vote.

The committee discussed Hemangeol (propranolol HCL oral solution)
The committee recommended to the department that Hemangeol (propranolol HCL oral solution) remain on PA by a unanimous vote. The committee recommended that clinical criteria require use of the generic propranolol solution.

The committee discussed Evzio (naloxone injection)
The committee recommended to the department that Evzio (naloxone injection) remain on PA by a unanimous vote. The committee recommended that clinical criteria require use of the preferred naloxone kits which include a prefilled syringe and nasal atomizer.

The committee discussed Tanzeum (albiglutide)
The committee recommended to the department that Tanzeum (albiglutide) remain on PA by a unanimous vote. The committee recommended that clinical criteria require trial and failure of Byetta.
The committee discussed Qudexy XR (topiramate extended-release)
The committee recommended to the department that Qudexy XR (topiramate extended-release) remain on PA by a unanimous vote. The committee recommended that clinical criteria require on-label use.

The committee discussed Jublia (efinaconazole)
The committee recommended to the department that Jublia (efinaconazole) remain on PA by a unanimous vote. The committee recommended that clinical criteria require use of ciclopirox for an entire treatment course and failure or contraindication to terbinafine.

New Specialty Drugs for Continued PA

The committee discussed Vimizim (elosulfase alfa)
The committee recommended to the department that Vimizim (elosulfase alfa) remain on PA by a unanimous vote. The committee recommended that clinical criteria require on-label use.

The committee discussed Otezla (apremilast)
The committee recommended to the department that Otezla (apremilast) remain on PA by a unanimous vote. The committee recommended that Otezla be added to the immunomodulator criteria in Tier 3 and use be kept on-label.

The committee discussed Orenitram ER (treprostinil)
The committee recommended to the department that Orenitram ER (treprostinil) remain on PA by a unanimous vote. The committee recommended that clinical criteria require a diagnosis of PAH and the recipient to have tried and failed sildenafil, letairis and inhaled treprostinil.

The committee discussed Myalept (metreleptin for injection)
The committee recommended to the department that Myalept (metreleptin for injection) remain on PA by a unanimous vote. The committee recommended that clinical criteria require on-label use.

The committee discussed Entyvio (vedolizumab)
The committee recommended to the department that Entyvio (vedolizumab) remain on PA by a unanimous vote. The committee recommended Entyvio be added to the immunomodulator category in Tier 3.

Adjournment
The meeting was adjourned at 9:15 pm CST.